Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a ...

Personalized medicine advances as autologous cell therapy grows, leveraging refined cell collection, improved processing ...

The asset in question, an autologous CAR-T dubbed ASP2802 aimed at CD20-positive B-cell lymphomas ... “important progress” and “drug development knowledge” that will benefit the company ...

In the article that accompanies this editorial, Bartlett et al 11 present the results of ECHELON-3, a phase III trial comparing brentuximab vedotin + lenalidomide + rituximab (BV + Len + R) with ...

A phase 1 clinical trial found one such immunotherapy to be safe for patients with several types of B-cell lymphoma, a type of blood cancer. Larger studies are needed to assess efficacy ...

A phase 1 clinical trial has found one such immunotherapy to be safe for patients with several types of B-cell lymphoma, a type of blood cancer. Larger studies are needed to assess efficacy ...

lymphoma and diffuse large B-cell lymphoma. Stage 3 HIV-associated lymphomas spread extremely fast. If left untreated, they can lead to death within weeks or months after receiving a diagnosis.

Patients were randomly assigned 1:1 to receive BV + Len + R or placebo + Len + R. Patients were stratified by CD30 expression (positive [≥1%] v negative [<1%]), cell of origin (germinal center B cell ...

While the trial was not designed to evaluate efficacy, Ghobadi and colleagues said that responses were observed across B-cell lymphoma histologies among those treated with the combination ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...